For almost three decades, a US prescription drug TV ad has been able to show a short statement of the most important risks, known as the major statement, and point viewers elsewhere for the rest: a toll-free number, a website, a print ad, or their doctor. That mechanism is called adequate provision, and it is the reason a 60-second drug ad can exist at all. In September 2025 FDA said it intends to end it. More than a year later the rule has not changed yet, but enforcement already has, and the direction is clear enough that brand, regulatory and agency teams should be planning for it now.
This guide covers what happened in the September 2025 enforcement wave, what the proposed rule would change in 21 CFR 202.1, which kinds of promotion are affected beyond television, and a practical checklist for reviewing DTC and digital content in 2026. It is written for the people who make and review promotional content. It is not legal advice, and your own regulatory and legal teams should interpret the rule once its text is published.
What is adequate provision, and why does it matter?
FDA's advertising regulation, 21 CFR 202.1, requires a prescription drug advertisement to include a true statement of information in brief summary about side effects, contraindications and effectiveness. Print ads usually meet this with the dense brief summary page that follows the ad itself. Broadcast ads were given an alternative: present the major statement of the product's most important risks in the ad, and make adequate provision for viewers to get the full approved labeling some other way.
FDA's 1999 guidance on consumer-directed broadcast advertisements described what adequate provision looks like in practice: a toll-free number, a reference to a concurrently running print ad or a website, and a statement that the viewer's healthcare provider can give more information. That combination is why US television drug ads look the way they do. The benefit story is told in the main body of the spot, the major statement runs over the closing section, and everything else lives one step away.
It also explains why broadcast DTC exists at all. The United States and New Zealand are the only countries that allow direct-to-consumer advertising of prescription drugs, and the US format depends on not having to fit full risk information into 30 or 60 seconds. Remove adequate provision and the economics of the format change completely.
The major statement itself was already tightened. FDA's final rule on the presentation of the major statement in TV and radio ads set a clear, conspicuous and neutral standard: consumer-friendly language, audio and text presented together in TV ads, and no distracting sounds or visuals while the risks are being described. Companies had to comply from November 2024. Adequate provision is the next piece.
What happened in the September 2025 enforcement wave?
On 9 September 2025, following a presidential memorandum on prescription drug advertising, HHS and FDA announced a coordinated push against misleading DTC promotion. FDA sent around 100 cease-and-desist letters to companies and issued a large batch of untitled letters, most of them about television advertising. FDA later published the letters on its website. Commentators noted that some of the letters did not follow the usual format of OPDP's warning and untitled letters, which is itself a signal that the agency was prepared to move outside its normal pattern.
The themes in the letters were familiar ones. Law-firm reviews of the batch found that omission or minimization of risk information was the most common issue, followed by efficacy claims that went further than the evidence supported, and presentations in which visuals, music or pacing competed with the risk information while it was being delivered. None of these are new standards. What changed was the volume, and the willingness to act on presentation as well as on wording.
FDA also said its scrutiny would not stop at television. The announcement covered digital and social promotion, including paid influencers, and the agency described using new tools to monitor promotional content at scale. For teams whose review process was built around a handful of high-profile TV spots, that is the more important change: the long tail of digital assets is now in scope in a way it rarely was before.
For context, the period before the crackdown was unusually quiet. OPDP issued only a handful of enforcement letters a year in 2023 and 2024, and some observers expected fewer still in 2025 after staffing cuts at FDA. The September wave reversed that expectation in a single day.
What would the proposed rule change?
FDA's regulatory agenda lists a proposed rule titled “Transparency in Direct-to-Consumer Advertising” that would amend 21 CFR 202.1 to remove the adequate provision option for broadcast advertisements. In practice, broadcast ads would have to carry the required risk information within the advertisement itself rather than pointing elsewhere for it. FDA's stated rationale is that adequate provision has been used to keep important safety information away from the people the ad is reaching.
As of November 2026 the proposal has not been published in the Federal Register. The agenda points to publication around the end of 2026, after which there will be a public comment period, typically 60 to 90 days. A final rule would follow later, most likely not before 2027, and challenges are possible. Check the Federal Register for the current status before making decisions that depend on dates.
If the rule is finalized as described, many broadcast formats become impractical. Commentators have called it a de facto ban on TV drug advertising, because fitting brief-summary-level risk information into a short spot leaves little room for anything else. The more realistic outcomes are fewer TV ads, longer formats where TV is still used, and budget moving to channels where full risk information fits naturally: digital, owned channels, point of care and HCP promotion.
What does not change is everything that already applies to every channel. Claims still have to be consistent with the approved labeling and supported by substantial evidence. Risk information still has to be presented with prominence comparable to benefit information. Those requirements are where most enforcement actually happens, and they will matter more, not less, as spend moves into channels that are reviewed less carefully today.
Which channels are affected beyond TV?
The proposed rule is about broadcast advertising, which today means television and radio. In practice, the line between broadcast and digital is blurry. Connected TV, streaming services, online video, podcasts and audio ads behave like broadcast for the viewer, and FDA has said that adequate provision has been misused in digital advertising as well. Teams should assume that any audio or video ad that relies on pointing elsewhere for risk information will be looked at under the same logic.
Social media has its own long-standing guidance. FDA's 2014 draft guidance on platforms with character space limitations says that a post making a benefit claim should also include the most serious risks within the same post, along with a link to more complete risk information. If the platform does not leave room for both, the guidance suggests reconsidering whether that platform is appropriate for the message. That logic is now the default way to think about every short-form format.
Influencer content is promotion. If a company pays for it, shapes it or provides the talking points, FDA treats it as the company's communication, with the same requirements for balance and substantiation. Telehealth platforms and creator partnerships that sit outside the normal agency workflow are exactly the kind of content that tends to bypass MLR review, and exactly the kind of content the 2025 announcement called out.
HCP promotion is not DTC, but it is covered by the same regulation and the same expectations about fair balance and consistency with labeling. OPDP continues to issue letters about HCP materials, including emails to physicians. A tighter climate for consumer advertising is not a reason to relax the review of field and medical-facing content.
A practical checklist for reviewing DTC content in 2026
Start with an inventory. List every live asset that relies on adequate provision or links away from risk information: TV and radio spots, connected TV and online video, audio ads, social posts, display banners and search ads. When the proposed rule is published, this list is your exposure, and building it now is far easier than building it under a deadline.
Review the risk side first, not the claim side. For every asset, ask whether the risk information is presented with prominence comparable to the benefits: the same screen time or space, readable size and contrast, and no music, visuals or pacing that pull attention away while it is delivered. The clear, conspicuous and neutral standard for the major statement is a useful bar to apply to every video format, not just TV.
Check the claims for the overstatement patterns that keep appearing in letters. Is every efficacy claim consistent with the label and supported by the evidence as worded? Do the visuals imply benefits beyond what was studied, such as a patient doing things the trial did not measure? Are relative risk reductions presented without the absolute numbers that give them meaning? Is the indication stated with its limitations?
Bring influencer, creator and telehealth partner content into the same review process as agency work, with the same records. Keep your submissions current: promotional materials are submitted to FDA on Form FDA 2253 at the time of first use, and drugs approved under accelerated approval face additional pre-submission requirements.
Finally, build risk information as an approved module that can expand. If an asset has a short risk block today, have the longer, fuller version approved and ready to drop in. When the rules change, teams with modular, pre-approved risk content will update assets in days. Teams rebuilding each asset by hand will take months.
Where SwishX fits
Magic Studio writes every asset, across Video, Docs, Ads, Approved Email and Web, from the claims and dossiers your team has already approved. Every claim is cited to its source and checked against the label for its market, fair balance and safety information are placed in the asset as it is made, and anyone can ask an asset where a line came from. Finished work goes into your MLR queue and on into Veeva PromoMats, rather than around it.
For teams reworking DTC and digital assets for a world without adequate provision, that means starting from approved risk information and approved claims every time, instead of rebuilding them asset by asset. The review still belongs to your reviewers. The difference is what reaches them.
Frequently asked questions
What does adequate provision mean in pharma advertising?
Adequate provision is the option in FDA's advertising rules that lets a broadcast prescription drug ad include only the major statement of the most important risks, as long as it gives viewers a way to get the full approved labeling elsewhere, typically a toll-free number, a website, a print ad and a statement that their healthcare provider can give more information.
Has FDA eliminated adequate provision?
Not as of November 2026. FDA has listed a proposed rule on its regulatory agenda that would remove the adequate provision option from 21 CFR 202.1, with publication expected around the end of 2026, followed by a public comment period. Check the Federal Register for the current status.
What did the FDA letters in September 2025 focus on?
Mostly omission or minimization of risk information, efficacy claims that went beyond the evidence, and presentations in which visuals, music or pacing distracted from the risk information. Most of the letters concerned television advertising, but FDA also signaled attention to digital, social and influencer promotion.
Does the proposed rule affect HCP promotion?
The proposed change targets broadcast direct-to-consumer advertising. HCP materials are already expected to present fair balance and to be accompanied by the full prescribing information, and OPDP continues to issue letters about HCP promotion, so the review standard for HCP content stays the same.
What should pharma brand teams do now?
Inventory every asset that relies on adequate provision or links away from risk information, review existing assets for risk prominence and overstated claims, bring influencer and partner content into MLR review, and prepare approved, expandable risk information modules so assets can be updated quickly when the rule is published.